Molecular Research on Myeloproliferative Disorders
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 12471
Special Issue Editors
2. Altius Institute for Biomedical Sciences, Seattle, WA 98121, USA
Interests: experimental hematology; hematopoietic stem cells; microenvironment; erythropoiesis; myeloproliferative neoplasms
Interests: hematopoietic stem cells; megakaryocytes; myeloproliferative neoplasms; bone marrow microenvironment; hematopoietic stem cells and other cells generated in vitro for therapy
Special Issue Information
Dear Colleagues,
The Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are chronic hematological malignancies which include polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Polycythemia vera and essential thrombocythemia are associated with increased numbers of myeloid cells including red cells, white blood cells and platelets with one lineage predominating depending on the individual disease. Polycythemia vera and essential thrombocythemia, however, are capable of clonal evolution and clinical progression over a decade or two to myelofibrosis, a state very similar to that of primary myelofibrosis, with ineffective hematopoiesis and fibrosis in the bone marrow and associated with a profound pro-inflammatory milieu. Myelofibrosis and primary myelofibrosis have disabling systemic symptoms, such as weight loss, early satiety, bone pain, and fevers, and present circulating malignant hematopoietic stem cells (HSC) which establish extramedullary hematopoiesis in sites such as the spleen. Over 50% of these patients eventually develop a form of acute leukemia termed MPN-blast crisis which is associated with an overall survival of <10 months. Recent progresses in our understanding of the landscape of genetic lesions associated with MPNs and advances in the power of the diagnostic tools are providing unprecedented opportunities to improve the prognosis and risk stratification and to develop personalized therapies for this class of disorders, some of which, such as primary myelofibrosis and its blast-crisis, are still an unmet clinical need. Authors are invited to submit original research and review articles which address the progress and current standing of the pathobiological pathways leading to MPNs.
Topics include, but are not limited to:
- Identification of novel genetic lesions.
- Insights provided by the genetic lesions on prognosis, risk stratification and personalized therapies.
- Hematopoietic stem cell abnormalities that may be exploited for therapy.
- Abnormalities in the interactions between the malignant HSC and their supportive microenvironment which drive disease progression.
- Role of the progeny (megakaryocytes, neutrophils, macrophages, and mast cells) of the malignant HSC in shaping the malignant HSC supportive microenvironment.
- The inflammosome and disease progression
- Advances is the diagnostic tools (Imaging, single cell sequencing, multi-plex single cell cytokine profiling, machine deep learning).
- Novel animal models.
Prof. Dr. Anna Rita Migliaccio
Prof. Dr. Ronald Hoffman
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Philadelphia chromosome-negative myeloproliferative neoplasms
- driver mutations
- pathobiological mechanisms
- disease interventions and biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.